New Research Poster Presentation 1.52
Efficacy and Safety of a Methylphenidate Extended-Release Chewable Tablet in Pediatric Patients With ADHD: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study
Wednesday, October 28, 2015 12:00 PM
Sharon Wigal, PhD, AVIDA Inc., Newport Beach, CA
Ann Catherine Childress, MD, Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV
Sally Berry, MD, PhD, NextWave Pharmaceuticals, Titusville, NJ
Heidi Belden, PharmD, Pfizer, Inc., Plymouth, MA
Faith Walters, PharmD, Medical Affairs, Global Established Products, Pfizer, Inc., New York, NY
Phillip Chappell, MD, MBA, CNS Clinical Affairs, Global Established Products, Pfizer, Inc., New York, NY
Nancy A. Sherman, BA, Pfizer, Inc., New York, NY
John Orazem, PhD, Pfizer, Inc., New York, NY
Donna Palumbo, PhD, Medical Affairs, Global Established Products, Pfizer, Inc., New York, NY
